Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Go back to Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults| (NASDAQ: CRNX) | Delayed: 83.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.72 | 52 Week High | $ | |||
| Open | $83.72 | 52 Week Low | $ | |||
| Day High | $83.72 | P/E | N/A | |||
| Day Low | $83.72 | EPS | $ | |||
| Volume | 207 | |||||
